Inhibitory Effects of Filiform Acupuncture and Laser Acupuncture at the Points of Zhongzhu(TE3Zulinqi(GB41) on Neuropathic Pain in the Tibial and Sural Nerve Injury-induced Rats

Article information

Acupunct. 2014;31(2):119-134
Publication date (electronic) : 2014 June 20
doi : https://doi.org/10.13045/acupunct.2014030
Department of Acupuncture and Moxibustion Medicine, College of Korean Medicine, Dongshin University
Corresponding author : Department of Acupuncture & Moxibustion Medicine, Dongshin Korean Medical Hospital, 351, Omok-ro, Yangcheon-gu, Seoul, 158-050, Republic of Korea, Tel : +82-2-2640-2931 E-mail : energizer80@hanmail.net
Received 2014 May 26; Revised 2014 May 26; Accepted 2014 May 28.

Abstract

Objectives:

The purpose of this study was to investigate the analgesic effects of filiform acupuncture and laser acupuncture at the points of TE3·GB41 in neuropathic pain induced rats.

Methods:

Neuropathic pain in rats was induced by partial resection of the tibial and sural nerves. Three weeks after the neuropathic surgery, each of the experimental groups(AT, LAT, AT + LAT and LAT + AT) was injected at the TE3·GB41 twice per week for three weeks.

Results:

  1. All of the experimental groups(AT, LAT, AT + LAT and LAT + AT) showed a significant decrease in the plantar withdrawal response of allodynia and the thermal allodynia as compared with the control group. During the early phase, the AT and AT + LAT groups have been marked as more significant than the LAT + AT and LAT groups.

  2. The expression of c-Fos significantly decreased in the LAT and LAT + AT groups as compared with the control group.

  3. The LAT + AT group showed a significant decrease in Bax as compared with the control group. In each experimental groups(AT, LAT, AT + LAT and LAT + AT), Bcl-2 increased and Bax/Bcl-2 ratio decreased as compared with the control group.

  4. The LAT, AT + LAT and LAT + AT groups showed a significant increase in mGluR5 as compared with the control group.

Conclusions:

These results represented that the filiform acupuncture and laser acupuncture at the TE3·GB41 exerted anti-apoptotic and neuroprotective effects on the model of neuropathic pain, thereby suggesting that they should be available for decreasing mechanical allodynia.

Fig. 1.

Effect of AT, LAT, AT + LAT and LAT + AT treatments on the reaction time of Von Frey in tibial and sural nerve injury rats

A description of controls and experimental groups refer to Table 1.

Effect of AT, LAT, AT + LAT and LAT + AT Treatments on the Reaction Time of Withdrawal Rresponse to Mechanical Allodynia in Tibial and Sural Nerve Injury Rats (sec)

## : p<0.01 compared with normal.

*: p<0.05, ** : p<0.01 compared with control.

Fig. 2.

Effect of AT, LAT, AT + LAT and LAT + AT treatments on the force of Von Frey in tibial and sural nerve injury rats

A description of controls and experimental groups refer to Table 1.

## : p<0.01 compared with normal.

*: p<0.05, ** : p<0.01 compared with control.

Fig. 3.

Effects of AT, LAT, AT + LAT and LAT + AT treatments on the trajectory of thermal gradient in tibial and sural nerve injury rats

A description of controls and experimental groups refer to Table 1.

Fig. 4.

Effect of AT, LAT, AT + LAT and LAT + AT Treatment on the c-Fos protein in tibial and sural Nerve injury rats

Values are expressed mean ± SE.

A description of controls and experimental groups refer to Table 1.

## : p<0.01 compared with normal.

**: p<0.01 compared with control.

Fig. 5.

Representive microphotographs of coronal sections for observation of c-Fos expression in central gray of brain of tibial and sural nerve injury rats

A description of controls and experimental groups refer to Table 1.

Fig. 6.

Effect of AT, LAT, AT + LAT and LAT + AT treatments on the Bax contents in tibial and sural nerve injury rats

Values are expressed mean ± SE

A description of controls and experimental groups refer to Table 1.

## : p<0.01 compared with normal.

**: p<0.01 compared with control.

Fig. 7.

Effect of AT, LAT, AT + LAT and LAT + AT treatments on the Bcl-2 contents in tibial and sural nerve injury rats

Values are expressed mean ± SE.

A description of controls and experimental groups refer to Table 1.

## : p<0.01 compared with normal.

*: p<0.05, ** : p<0.01 compared with control.

Fig. 8.

Effect of AT, LAT, AT + LAT and LAT + AT treatments on the Bax/Bcl-2 ratio in tibial and sural nerve injury rats

Values are expressed mean ± SE.

A description of controls and experimental groups refer to Table 1. ## : p<0.01 compared with normal.

*: p<0.05 compared with control.

Fig. 9.

Effect of AT, LAT, AT + LAT and LAT + AT treatments on the mGluR5 contents in tibial and sural nerve injury rats

Values are expressed mean ± SE.

A description of controls and experimental groups refer to Table 1.

## : p<0.01 compared with normal.

*: p<0.05 compared with control.

Effect of AT, LAT, AT + LAT and LAT + AT Treatments on the Force Intensity of Withdrawal Response to Mechanical Allodynia in Tibial and Sural Nerve Injury Rats (g)

Effect of AT, LAT, AT + LAT and LAT + AT Treatments on the Activity of c-Fos Protein in the Central Gray of Brain of Tibial and Sural Nerve Injury Rats

Effect of AT, LAT, AT + LAT and LAT + AT Treatments on the Bax Contents in Tibial and Sural Nerve Injury Rats

Effect of AT, LAT, AT + LAT and LAT + AT Treatments on the Bcl-2 Contents in Tibial and Sural Nerve Injury Rats

Effect of AT, LAT, AT + LAT and LAT + AT Treatments on the Bax/Bcl-2 Contents in Tibial and Sural Nerve Injury Rats

Effect of AT, LAT, AT + LAT and LAT + AT Treatments on the mGluR5 Contents in Tibial and Sural Nerve Injury Rats

References

1. Merskey H, Bogduk N. Classification of chronic pain 2nd edth ed. Seattle: IASP Press; 1994. p. 209–14.
2. Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008;70:1630–5.
4. Woolf CJ, Mannion RJ. Neuropathic pain: aetiology, symptoms, mechanisms, and management. The Lancet 1999;353:1959–64.
5. Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain 2006;7(4):281–9.
6. Bouhassira D, Lantéri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2008;136(3):380–7.
7. Hecke O, Austin SK, Khan RA, Smith BH, Torrance N. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain 2014;155(4):654–62.
8. Colombo B, Annovazzi POL, Comi G. Medications for neuropathic pain: current trends. Neurological Sci 2006;27:S183–9.
9. Nanjing University of Chinese Medicine. The annotation of The Huang Di Nei Jing-So Moon Shanghai: Shanghai Scientific and Technical Publishers; 1997. 278p. 305–12. p. 361. p. 652.
10. Yue Zhang Jing. Lei Jing 1Seoul: Daesung Publisher; 1982. p. 372–5.
11. Nanjing University of Chinese Medicine. The annotation of The Huang Di Nei Jing-Young Chu Shanghai: Shanghai Scientific and Technical Publishers; 1997. 1p. 96–113.
12. Korean Acupuncture & Moxibustion Society. Acupuncture and moxibustion 2nd edth ed. Gyeonggi: Jipmoondang; 2008. p. 130–1.
13. Kim YU. A study on the Su Hyel Lon of the Nan gyeong. The Journal of the Korea Institue of Oriental Medical Infomatics 2009;15(1):11–55.
14. Korean Acupuncture & Moxibustion Medicine Society. Acupuncture and moxibustion medicine Gyeonggi: Jipmoondang; 2012. 16p. 225–30.
15. Jung JH, Yun DW, Na CS, Ryu CR, Yun YC, Cho MR. Effects of acupuncture at SI3, BL40, SI3, BL40 on neuropathic pain control and c-Fos protein expression in rats. The Journal of Korean Acupuncture and Moxibustion Society 2004;21(1):240–51.
16. Lee DH, Youn DH, Na CS, Yoon YC. Effects of bee venom acupuncture injected at Hwando(GB30) on neuropathic pain in rats. The Journal of Korean Acupuncture and Moxibustion Society 2005;22(5):67–77.
17. Chiang SY, Bang SP, Kim JH, Wei TS, Yun YC. Effects of bee venom acopuncture at Sinsu(BL23) and Daejangsu(BL25) in different concentration on neuropathic pain induced by tibial and sural nerve injury in rats. The Journal of Korean Acupuncture and Moxibustion Society 2010;27(5):13–24.
18. Oh CL, Na CS, Ryu CR, Cho MR. Inhibitory effects of electroacupuncture & acupuncture at Hu-gye (SI3), Wijung(BL4O), Hu-gye(SI3) and Wijung(BL40) on neuropathic pain in rats. The Journal of Korean Acupuncture and Moxibustion Society 2005;22(1):77–90.
19. Wei TS, Youn DH, Youn YC, Na CS. Comparative study of acupuncture and invasive laser acupuncture therapy at SI3·BL40 on the tibial, sural nerve injury and L5 spinal nerve ligation model in rats. Korean Journal of Acupuncture 2005;22(2):9–24.
20. Jung JH, Cho MR, Wei TS, Ryu CR. Effects of acupuncture, electro-acupuncture, low level He-Ne laser therapy at Oe-gwan(TE5Chogimup (GB41) on L5 spinal nerve ligation model in rats. The Journal of Korean Acupuncture and Moxi-bustion Society 2007;24(5):137–50.
21. Lambert GA, Mallos G, Zagami AS. Von Frey’s hairs-a review of their technology and use-a novel automated von Frey device for improved testing for hyperalgesia. Journal of Neuroscience Methods 2009;177(2):420–26.
22. Shir Y, Seltzer Z. Effects of sympathectomy in a model of causalgiform pain produced by partial sciatic nerve injury in rats. Pain 1991;45(3):309–20.
23. Yalcin I, Charlet A, Freund-Mercier M, Barrot M, Poisbeau P. Differentiating thermal allodynia and hyperalgesia using dynamic hot and cold plate in rodents. Journal of Pain 2009;10(7):767–73.
24. Woolf CJ. What is this thing called pain? Journal of Clinical Investigation 2010;120(11):3742–4.
25. Yoon DM. Neuropathic pain. The Korean Journal of Pain 1995;8(2):219–24.
26. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain 2010;150:573–81.
27. Attal N, Cruccu G, Baron R, et al. EFNS guidelines on pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010;17:1113–23.
28. Yun YC, Choi KJ, Chae WS, Na CS, Song HK. Effect of acupuncture(Hapkok, LI4) based on retaining time on pain in rats. The Journal of Korean Acupuncture and Moxibustion Society 1998;15(2):319–29.
29. Di Ding Gūng. The annotation of Treatise on the Pathogenesis and Manifestations of All Diseases 1st edth ed. Beijing: People’s Medical Publishing House; 1992. p. 152.
30. Kim HH, Nam DW, Lee SH. Fundamentals and research trend of laser acupuncture. The Journal of Korean Acupuncture and Moxibustion Society 2009;26(6):21–30.
31. Na CS, Youn DH, Choi CH, Lee SH, Oh KH, Jeong SH. The effects of traditional acupuncture techniques and green laser acupuncture on the blood pressure in hypertensive rat induced by two kidney one clip. Korean Journal of Acupuncture 2008;25(2):199–210.
32. Ihm SJ, Youn DH, Na CS. Effects of invasive low level laser acupuncture therapy(LLLAT) at LU7, LR5, LU7 + LR5 on the hyperlipemia rats induced by high fat diet. Korean Journal of Acupuncture 2005;22(3):1–15.
33. Kim WI, Youn DH, Choi CH, Na CS. Effects of low level laser treatment at LR2 and LR8 acupoint on the liver damage induced in D-GalN in rats. Korean Journal of Acupuncture 2012;29(1):131–41.
34. Youn JY, Kim YS, Youn DH, et al. Comparative studies of effects of manual acupuncture, invasive laser acupuncture and laser skin irradiation at the Heart Jeonggyeok acupoint on the focal ischemia induced by intraluminal filament insertion in rats. Korean Journal of Acupuncture 2010;27(1):125–42.
35. Lim JA, Chae WS, Lee SH, Jeong SH, Youn DH, Na CS. Effects of GaAlAs laser and acupuncture therapy at BL40 on neuropathic pain in rats. Korean Journal of Acupuncture 2011;28(2):37–47.
36. Kim YS, Lee JH, Lee SH, Na CS, Cho MR. Effects of electro and laser acupuncture treatment with GB39 and GB34 on neuropathic pain in rats induced by tibial and sural nerve ligation. The Journal of Korean Acupuncture and Moxibustion Medicine Society 2013;30(3):125–34.
37. Korean Acupuncture & Moxibustion Society. Acupuncture and moxibustion 1st edth ed. Gyeonggi: Jipmoondang; 2008. 201p. 249–50.
38. Lee OJ, Yun MY, Kim HH, Jo NG. Clinical study on a case of cervical myelopathy. The Journal of Korean Acupuncture and Moxibustion Society 2003;20(4):220–9.
39. Seo BM, Yun JS, Kim SU, et al. Comparison of treatment effect between oriental medicine theraphy and oriental and western medicine combination theraphy on low back pain patients. The Journal of Korean Acupuncture and Moxibustion Society 2003;20(6):140–7.
40. Choi IH. A clinical study of tinnitus. The Journal of Oriental Medical Surgery, Ophthalmology & Otolaryngology 2001;14(2):134–45.
41. Ha CH, Han SG, Cho MR, Lee BR, Ryu CR. A clinical study on 29 cases with stroke treated by common acupuncture therapy and scalp acupunture. The Journal of Korean Acupuncture and Moxibustion Society 2001;18(4):82–90.
42. Kim HJ, Ryu CR, Cho MR. Effects of Joongjeo (TE3) supplementation Aekmoon(TE2) draining on changes in cerebral blood flow and blood pressure in normal rats. The Journal of Korean Acupuncture and Moxibustion Society 2008;25(6):1–12.
43. Lim MJ, Ryu CR, Cho MR. Effects of Imeup(GB41) supplementation and Tonggok(BL66) draining on changes in cerebral hemodynamics in normal rats. The Journal of Korean Acupuncture and Moxibustion Society 2008;25(5):1–10.
44. Yoon CY. Function disease symptom and organ coordination of tri-energizer based on the materiality of tri-energizer. J Oriental Medical Classics 2013;26(2):1–7.
45. Ernst E, Fialka V. Ice freezes pain? A review of the clinical effectiveness of analgesic cold therapy. Journal of Pain and Symptom Management 1994;9(1):56–9.
46. Milde-Langosch K. The Fos family of transcription factors and their role in tumourigenesis. European Journal of Cancer 2005;41(16):2449–61.
47. Hu E, Mueller E, Oliviero S, Papaioannou VE, Johnson R, Spiegelman BM. Targeted disruption of the c-fos gene demonstrates c-fos-dependent and -independent pathways for gene expression stimulated by growth factors or oncogenes. The EMBO Journal 1994;13(13):3094–103.
48. Hunt SP, Pini A, Evan G. Induction of c-fos-like protein in spinal cord neurons following sensory stimulation. Nature 1987;328:632–4.
49. Harris JA. Using c-fos as a neural marker of pain. Brain Research Bulletin 1998;45(1):1–8.
50. Choi JH. Bax protein in cancer treatment. Journal of the Korean Medical Association 2007;50(11):1016–22.
51. Novellis V, Siniscalco D, Galderisi U, et al. Blockade of glutamate mGlu5 receptors in a rat model of neuropathic pain prevents early over-expression of pro-apoptotic genes and morphological changes in dorsal horn lamina II. Neuropharmacology 2004;46(4):468–79.
52. Kim HK, Kim PJ, Baik SW, Kim IS, Chung KS. Molecular biologic study on tbe changes of glutamate receptor(mGluR5) in rat hippocampus after brain ischemia. The Korean Journal of Critical Care Medicine 2000;15(2):75–81.

Article information Continued

Fig. 1.

Effect of AT, LAT, AT + LAT and LAT + AT treatments on the reaction time of Von Frey in tibial and sural nerve injury rats

A description of controls and experimental groups refer to Table 1.

Effect of AT, LAT, AT + LAT and LAT + AT Treatments on the Reaction Time of Withdrawal Rresponse to Mechanical Allodynia in Tibial and Sural Nerve Injury Rats (sec)

## : p<0.01 compared with normal.

*: p<0.05, ** : p<0.01 compared with control.

Fig. 2.

Effect of AT, LAT, AT + LAT and LAT + AT treatments on the force of Von Frey in tibial and sural nerve injury rats

A description of controls and experimental groups refer to Table 1.

## : p<0.01 compared with normal.

*: p<0.05, ** : p<0.01 compared with control.

Fig. 3.

Effects of AT, LAT, AT + LAT and LAT + AT treatments on the trajectory of thermal gradient in tibial and sural nerve injury rats

A description of controls and experimental groups refer to Table 1.

Fig. 4.

Effect of AT, LAT, AT + LAT and LAT + AT Treatment on the c-Fos protein in tibial and sural Nerve injury rats

Values are expressed mean ± SE.

A description of controls and experimental groups refer to Table 1.

## : p<0.01 compared with normal.

**: p<0.01 compared with control.

Fig. 5.

Representive microphotographs of coronal sections for observation of c-Fos expression in central gray of brain of tibial and sural nerve injury rats

A description of controls and experimental groups refer to Table 1.

Fig. 6.

Effect of AT, LAT, AT + LAT and LAT + AT treatments on the Bax contents in tibial and sural nerve injury rats

Values are expressed mean ± SE

A description of controls and experimental groups refer to Table 1.

## : p<0.01 compared with normal.

**: p<0.01 compared with control.

Fig. 7.

Effect of AT, LAT, AT + LAT and LAT + AT treatments on the Bcl-2 contents in tibial and sural nerve injury rats

Values are expressed mean ± SE.

A description of controls and experimental groups refer to Table 1.

## : p<0.01 compared with normal.

*: p<0.05, ** : p<0.01 compared with control.

Fig. 8.

Effect of AT, LAT, AT + LAT and LAT + AT treatments on the Bax/Bcl-2 ratio in tibial and sural nerve injury rats

Values are expressed mean ± SE.

A description of controls and experimental groups refer to Table 1. ## : p<0.01 compared with normal.

*: p<0.05 compared with control.

Fig. 9.

Effect of AT, LAT, AT + LAT and LAT + AT treatments on the mGluR5 contents in tibial and sural nerve injury rats

Values are expressed mean ± SE.

A description of controls and experimental groups refer to Table 1.

## : p<0.01 compared with normal.

*: p<0.05 compared with control.

Table 1.

Effect of AT, LAT, AT + LAT and LAT + AT Treatments on the Reaction Time of Withdrawal Rresponse to Mechanical Allodynia in Tibial and Sural Nerve Injury Rats (sec)

Group Injury of tibial &sural nerve Treatment(times)
Before After 1st 2nd 3rd 4th 5th 6th
Nor 7.2 ± 0.1 7.4 ± 0.3 7.4 ± 0.4 7.2 ± 0.5 7.4 ± 0.1 6.9 ± 0.2 6.8 ± 0.3 7.0 ± 0.3
Con 7.1 ± 0.1 4.0 ± 0.2## 3.4 ± 0.4## 3.2 ± 0.4## 3.4 ± 0.6## 3.5 ± 0.5## 3.7 ± 0.5## 4.0 ± 0.2##
AT 7.1± 0.2 4.1± 0.4 4.8± 0.1* 5.5 ± 0.3** 4.5 ± 0.3 5.1 ± 0.3** 5.2 ± 0.5* 5.6 ± 0.3**
LAT 7.3 ± 0.2 4.3 ± 0.4 3.9 ± 0.3 4.3 ± 0.4 4.6 ± 0.6 4.8 ± 0.5* 5.2 ± 0.3* 5.8 ± 0.3**
AT + LAT 7.2 ± 0.2 4.3 ± 0.2 4.5 ± 0.3 4.3 ± 0.3* 4.2 ± 0.6 4.5 ± 0.3 5.1 ± 0.6 5.7 ± 0.2**
LAT + AT 7.2 ± 0.1 4.1 ± 0.3 4.0 ± 0.3 4.7 ± 0.8 4.9 ± 0.2* 5.4 ± 0.4** 5.9 ± 0.6* 5.8 ± 0.3**

Values are expressed mean ± SE.

Nor : normal group.

Con : tibial and sural nerve injury and no treatment group.

AT : tibial and sural nerve injury and traditional acupuncture treatment at TE3·GB41.

LAT : tibial and sural nerve injury and low level laser 830 nm treatment at TE3·GB41.

AT + LAT : tibial and sural nerve injury and traditional acupuncture treatment + low level laser 830 nm treatment at TE3·GB41.

LAT + AT : tibial and sural nerve injury and low level laser 830 nm treatment + traditional acupuncture treatment at TE3·GB41.

##

p<0.01 compared with normal.

*

p<0.05,

**

p<0.01 compared with control.

Table 2.

Effect of AT, LAT, AT + LAT and LAT + AT Treatments on the Force Intensity of Withdrawal Response to Mechanical Allodynia in Tibial and Sural Nerve Injury Rats (g)

Group Injury of tibial & sural nerve Treatment(times)
Before After 1st 2nd 3rd 4th 5th 6th
Nor 35.6 ± 0.3 37.0 ± 1.6 37.0 ± 2.0 35.9 ± 2.6 36.1 ± 1.0 34.8 ± 1.0 34.0 ± 1.4 34.3 ± 0.8
Con 35.3 ± 0.4 19.5 ± 1.1## 17.2 ± 1.7## 16.3 ± 1.8## 17.0 ± 3.0## 17.5 ± 2.2## 18.8 ± 2.7## 20.3 ± 1.1##
AT 35.4 ± 0.8 20.4 ± 2.0 24.0 ± 0.4** 27.5 ± 1.3** 22.8 ± 1.3 25.7 ± 1.4** 26.3 ± 2.3* 28.0 ± 1.6**
LAT 35.9 ± 0.7 19.4 ± 2.2 19.7 ± 1.4 21.7 ± 2.1 23.4 ± 2.9 24.2 ± 2.3* 25.9 ± 1.7* 29.4 ± 1.3**
AT + LAT 36.0 ± 0.9 18.1 ± 1.1 22.8 ± 1.2* 21.8 ± 1.6* 21.2 ± 2.8 23.0 ± 1.5* 25.6 ± 2.9 28.8 ± 0.9**
LAT + AT 35.7 ± 0.1 18.2 ± 1.6 20.3 ± 1.3 23.8 ± 4.0 24.7 ± 1.2* 27.2 ± 1.9** 29.4 ± 3.0* 29.2 ± 1.4**

Values are expressed mean ± SE.

A description of controls and experimental groups refer to Table 3.

Effect of AT, LAT, AT + LAT and LAT + AT Treatments on the Total Distance of Thermal Gradient in Tibial and Sural Nerve Injury Rats (%)

##

p<0.01 compared with normal.

*

p<0.05,

**

p<0.01 compared with control.

Table 3.

Effect of AT, LAT, AT + LAT and LAT + AT Treatments on the Total Distance of Thermal Gradient in Tibial and Sural Nerve Injury Rats (%)

Group Before (baseline) Treatment(times)

2 4 6
Nor 100.0 ± 0.0 108.0 ± 7.6 103.0 ± 4.4 108.9 ± 11.7
Con 100.0 ± 0.0 121.1 ± 8.0 124.1 ± 5.3# 128.9 ± 6.7
AT 100.0 ± 0.0 123.8 ± 8.0 112.6 ± 6.7 98.2 ± 9.0*
LAT 100.0 ± 0.0 137.5 ± 11.7 133.5 ± 29.6 102.3 ± 5.0*
AT + LAT 100.0 ± 0.0 111.1 ± 18.2 105.2 ± 17.0 99.3 ± 11.9*
LAT + AT 100.0 ± 0.0 113.6 ± 17.1 120.4 ± 18.4 93.4 ± 12.8*

Values are expressed mean ± SE.

A description of controls and experimental groups refer to Table 3.

#

p<0.05 compared with normal.

*

p<0.05 compared with control.

Table 4.

Effect of AT, LAT, AT + LAT and LAT + AT Treatments on the Activity of c-Fos Protein in the Central Gray of Brain of Tibial and Sural Nerve Injury Rats

Group c-Fos protein(EA)
Nor 6.0 ± 0.4
Con 29.8 ± 2.3##
AT 24.0 ± 0.8
LAT 18.5 ± 0.5**
AT + LAT 19.8 ± 4.2
LAT + AT 14.5 ± 1.8**

Values are expressed mean ± SE.

A description of controls and experimental groups refer to Table 3.

##

p<0.01 compared with normal.

**

p<0.01 compared with control.

Table 5.

Effect of AT, LAT, AT + LAT and LAT + AT Treatments on the Bax Contents in Tibial and Sural Nerve Injury Rats

Group Bax(× 1,000 OD)
Nor 90.1± 1.3
Con 132.1 ± 1.6##
AT 127.8 ± 1.9
LAT 130.9 ± 1.8
AT + LAT 126.3 ± 2.7
LAT + AT 108.9 ± 1.7**

Values are expressed mean ± SE.

A description of controls and experimental groups refer to Table 3.

##

p<0.01 compared with normal.

**

p<0.01 compared with control.

Table 6.

Effect of AT, LAT, AT + LAT and LAT + AT Treatments on the Bcl-2 Contents in Tibial and Sural Nerve Injury Rats

Group Bcl-2(× 1,000 OD)
Nor 128.2 ± 2.8
Con 83.7 ± 7.2##
AT 114.1 ± 4.8*
LAT 111.7 ± 2.6*
AT + LAT 118.9 ± 2.4**
LAT + AT 109.2 ± 2.2*

Values are expressed mean ± SE.

A description of controls and experimental groups refer to Table 3.

##

p<0.01 compared with normal.

*

p<0.05,

**

p<0.01 compared with control.

Table 7.

Effect of AT, LAT, AT + LAT and LAT + AT Treatments on the Bax/Bcl-2 Contents in Tibial and Sural Nerve Injury Rats

Group Bax/Bcl-2 ratio
Nor 0.70 ± 0.02
Con 1.60 ± 0.13##
AT 1.12 ± 0.04*
LAT 1.17 ± 0.04*
AT + LAT 1.06 ± 0.04*
LAT + AT 1.00 ± 0.03*

Values are expressed mean ± SE.

A description of controls and experimental groups refer to Table 3.

##

p<0.01 compared with normal.

*

p<0.05 compared with control.

Table 8.

Effect of AT, LAT, AT + LAT and LAT + AT Treatments on the mGluR5 Contents in Tibial and Sural Nerve Injury Rats

Group mGluR5(× 1,000 OD)
Nor 136.2 ± 2.4
Con 117.2 ± 1.6##
AT 120.6 ± 2.2
LAT 129.3 ± 2.3*
AT + LAT 131.3 ± 2.4*
LAT + AT 134.0 ± 3.3*

Values are expressed mean ± SE.

A description of controls and experimental groups refer to Table 3.

##

p<0.01 compared with normal.

*

p<0.05 compared with control.